Register
Login:
Share:
Email Facebook Twitter


London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England


Member Info for Nextlink


Send a private message to Nextlink

Member Since: Fri, 31st May 2013

Number of Share Chat Posts (all time): 217
Number of Share Chat Posts (last 30 days): 4

Last Posted: 16 May '19


Post Distribution over the last 30 days




16 May '19

Could be seeing the last of Venn Life Sciences 30 million shares.
14 May '19

Like you I held on Ofex.
As to reinstating the Dividend I feel we are very much in a
Growth stage.
We have cash to draw down for further acquisitions, which
will increase debt in the near term.
In that case I would happily continue to forgo a Dividend to see reducing debt
and increasing profit.
14 May '19

Since the Suspension Notice in September 2016 we have had
three announcements up to March this year.
In the last six weeks we have had nine.
It is hard to believe there is not a potential deal in the offing.
I have located a new private Company listed with Companies House, which
may indicate the target.
However, apart from being wrong, I will say no more on a public forum, to
avoid causing any issues to Highway Capital at this critical stage.
10 May '19

Regardless of a possible Trading Update, results are due in June.
Here we are with almost half the current Market Cap in cash.
Steps taken last year to permit payment of a Dividend.
A few investments reaching maturity.
7 Apr '19

Resolution 13 if passed will allow the Directors to put aside the requirement to offer
new shares, up to 52 million to existing shareholders.
This authority to be valid until the next AGM.
If they were to execute an RTO this would be a necessary step.

That's my take on this.
Hoping they have a target in sight.
All this frantic activity suggests that they do.
5 Apr '19

I agree insufficient cash was raised and current SP is aggravating this.
However Journalists are cheap and two a penny.
Good Software Developers are scarce and expensive.
Daily Mash integrated with their existing business should generate
economies of scale.
That said I think it will be a slow climb back to IPO SP with a strong
possibility of Dilution en route.
I've put these in the bottom draw and concentrating on other investments.
5 Apr '19

I was impressed by the progress they were making on all fronts
when they updated us on 24th January.
Over two months since that update, given they are not hanging about,
more news cannot be far off.
4 Apr '19

Looking at recent trades it is fair to say there is very little
confidence.
Their last Trading Update in November states that trading is in line with expectations.
That statement being made since they drew on £1.9 million unsecured loan note.
It certainly suggests that the results will be reasonable.
Personally I am not tempted by the weak SP rather see the results on Tuesday first.
28 Mar '19

Possible.
Then again we could just see a repeat of today if someone is stake building.
21 Mar '19

I do not know the answer to most of your questions.
However regarding DMH.
Some have suggested Daniel Mark Harrison is a worthless fraudster.
Obviously I do not know if that is true.
19 Mar '19

Thank you I see it now £1,043,701.
No indication as to whether this is merely preparatory
or they already have a deal in sight.
I'd like to think the latter, hence all the activity.
Reversing the loan to Mylux and writing off a £10.725 investment.
19 Mar '19

Appreciate Accounts Published relate to the past ie 2018.
There is no mention of 42.5 million new shares.
So I guess all being well further news will arrive in the near future.
18 Mar '19

Good news, as you say still hope.
18 Mar '19

Good to see they are moving ahead on the retinitis pigmentosa (RP).
I believe they were originally scheduled for June.
15 Mar '19

directinggas - shareholders would not have to worry about what
Scancell would be worth in administration as they would have lost
their entire investment.
I would hope administration never arises.
11 Mar '19

Knowlesi sadly I agree with you that the sp is far more likely to
continue it's downward trend.
Fortunately I exited several years ago and nothing I have seen of
late leads me to consider buying at this time.
Plenty of other opportunities out there, most of my shares are
going up, not something that can often be said of Scancell of late.
10 Mar '19

Another which has a candidate for inherited retinal dystrophy
https://www.biopharma-reporter.com/Article/2019/02/25/Roche-acquires-Spark-Therapeutics-for-4.3bn

Spark Theraputics have many other trials, in particular a treatment for haemophilia.
Reneuron is clearly not worth $4.3bn, perhaps not even £500 million
10 Mar '19

As I understand it MM's try to keep their book square.
So tend not to have many shares at the end of each days trading.
They may have a small free float to satisfy Normal Market size.
9 Mar '19

Only bought in this month on RP results.
Until recently I was only aware of their stroke trials, which have absorbed
huge amounts of cash.
Fascinated to see they have other trials, at much earlier stages.
Only starting to look at the Retinal Pigmentosa field.
I see that Biogen have bought Nightstar Therapeutics
Whilst at Phase 111, their treatment is for a rare inherited condition.
So Reneuron whilst at a very early stage has a much bigger market.
No doubt other companies out there, just begining to look.
Reckon we have a good week ahead -8.5% of Invesco's shares missing.
It can't all be Private Investors buying that amount.


Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days
Pdub2,518
Alfacomp2,367
langtro1,776
Wassatt1,547
Sanchez5991,470
BigBiteNow1,404
RichKen1,143
BoomerBower1,132





Member Login

Forgotten your password?
Email:

Password:


Don't have an account? Click here to Register Free!




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.